Samsung Biologics signs CMO agreement with U.S. company
Samsung Biologics inked a $112.5 million contract manufacturing organization (CMO) letter of intent with an unnamed U.S. biopharmaceutical firm, the Korean company said in a regulatory filing on Monday.